A Phase II, Open-Label, Multi-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects.

Trial Profile

A Phase II, Open-Label, Multi-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2011

At a glance

  • Drugs Influenza A virus vaccine-H5N1; MF 59
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 18 Nov 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top